Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer Journal Article


Authors: ten Hoorn, S.; Waasdorp, C.; van Oijen, M. G. H.; Damhofer, H.; Trinh, A.; Zhao, L.; Smits, L. J. H.; Bootsma, S.; van Pelt, G. W.; Mesker, W. E.; Mol, L.; Goey, K. K. H.; Koopman, M.; Medema, J. P.; Tuynman, J. B.; Zlobec, I.; Punt, C. J. A.; Vermeulen, L.; Bijlsma, M. F.
Article Title: Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer
Abstract: Background: Recently it has been recognized that stromal markers could be used as a clinically relevant biomarker for therapy response and prognosis. Here, we report on a serum marker for stromal activation, A Disintegrin and Metalloprotease 12 (ADAM12) in colorectal cancer (CRC). Methods: Using gene expression databases we investigated ADAM12 expression in CRC and delineated the source of ADAM12 expression. The clinical value of ADAM12 was retrospectively assessed in the CAIRO2 trial in metastatic CRC with 235 patients (31% of total cohort), and an independent rectal cancer cohort (n = 20). Results: ADAM12 is expressed by activated CRC associated fibroblasts. In the CAIRO2 trial cohort, ADAM12 serum levels were prognostic (ADAM12 low versus ADAM12 high; median OS 25.3 vs. 17.1 months, HR 1.48 [95% CI 1.11–1.96], P = 0.007). The prognostic potential was specifically high for metastatic rectal cancer (HR 1.78 [95% CI 1.06–3.00], P = 0.030) and mesenchymal subtype tumors (HR 2.12 [95% CI 1.25–3.60], P = 0.004). ADAM12 also showed potential for predicting recurrence in an exploratory analysis of non-metastatic rectal cancers. Conclusions: Here we describe a non-invasive marker for activated stroma in CRC which associates with poor outcome, especially for primary cancers located in the rectum. © 2022, The Author(s).
Keywords: retrospective studies; genetics; colorectal cancer; biomarkers; biological marker; metabolism; colonic neoplasms; pathology; retrospective study; tumor marker; colorectal neoplasms; colorectal tumor; colon tumor; stroma; rectal neoplasms; rectum tumor; cancer associated fibroblast; prognostic marker; adam12; humans; prognosis; cancer-associated fibroblasts; human; biomarkers, tumor; adam12 protein; adam12 protein, human
Journal Title: BMC Cancer
Volume: 22
ISSN: 1471-2407
Publisher: Biomed Central Ltd  
Date Published: 2022-04-12
Start Page: 394
Language: English
DOI: 10.1186/s12885-022-09436-0
PUBMED: 35413826
PROVIDER: scopus
PMCID: PMC9004139
DOI/URL:
Notes: Article -- Export Date: 2 May 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors